Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy

Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that efficiently delivers a highly potent microtubule inhibitor to HER2 overexpressing cells. Herein, we utilize HER2 transformed human mammary epithelial cells (HME2) to demonstrate in vitro and in vivo response and recurrence upon T...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhand, Saeed S., Chen, Hao, Purdy, Stephen Connor, Liu, Zian, Anderson, Joshua C., Willey, Christopher D., Wendt, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820437/
https://www.ncbi.nlm.nih.gov/pubmed/33479246
http://dx.doi.org/10.1038/s41523-020-00213-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820437/
https://www.ncbi.nlm.nih.gov/pubmed/33479246
http://dx.doi.org/10.1038/s41523-020-00213-5

Ejemplares similares